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L ooking B ack , M oving F orward

Access to Antiretroviral Therapy for
HIV Infected Adults and Children in
Developing Countries

Horizons Studies 2002 to 2008

In 1997, the Population Council initiated the Horizons Program—a decade-long USAID-funded collaboration with the International Center for Research on Women, the International HIV/AIDS Alliance, PATH,
Tulane University, Family Health International, and Johns Hopkins University—designing, implementing,
evaluating, and expanding innovative strategies for HIV prevention and care.
Horizons developed and tested ways to optimize HIV prevention, care, and treatment programs; worked to
reduce stigma and improve gender-biased behaviors; and greatly expanded knowledge about the best ways to
support, protect, and treat children affected by HIV and AIDS. In all its projects, Horizons strengthened the
capacity of local institutions by providing support and training to colleagues.
This series of synthesis papers presents lessons learned and best practices on six key topics that Horizons
investigated: HIV-related stigma, access to antiretroviral therapy, men who have sex with men, orphans and
vulnerable children, HIV and gender, and prevention of mother-to-child transmission of HIV.

Credit: AVINA SARNA/POPULATION COUNCIL

Access to Antiretroviral Therapy for
HIV Infected Adults and Children in
Developing Countries
The advent of life-saving antiretroviral therapy (ART) for people living with HIV
in the late 1990s promised to avert millions of deaths to AIDS. However, in
resource-constrained settings hard hit by the epidemic, providers and people living
with HIV faced numerous challenges to the effective delivery and uptake of treatment services. In 2001, Horizons began its investigation of the rollout and provision of ART in Asia and Africa in order to answer key questions surrounding service
delivery, health seeking behaviors, adherence, cost, and barriers to treatment for
HIV-infected adults and children. Horizons researchers found that provision of and
adherence to ART regimens is hindered by a lack of knowledge among providers
and affected communities, a lack of linkages between key services, and by stigma
surrounding HIV. Our research has been used to break down these barriers and to
guide global efforts toward ensuring full access and adherence to treatment across
diverse settings.

Introduction
In the late 1990s, increased accessibility of
life-extending antiretroviral therapy (ART)
changed the face of the AIDS epidemic around
the world. Although Brazil, Thailand, Senegal,
and Botswana were providing ART for adults
through public sector health facilities as early
as 2000, government treatment programs in
other countries hard hit by HIV in the developing world were not established until 2002
or later. ART services for children were started
even later. Program managers in low resource
settings rapidly raised questions regarding the
best way to roll-out treatment programs: What
were the key elements of health care readiness

needed to offer ART services? What was the
best way to train staff providing services? And
what could be done to promote adherence to
therapy? There was virtually no relevant evidence to answer these questions.
To respond to these questions, the Horizons
Program convened a meeting of international
experts in 2001 to explore the operational challenges related to the introduction of therapy in
developing country settings and to prioritize
research questions around access to ART [1].
Following this meeting Horizons embarked on
a research program that eventually included 11
projects (Appendix) across Asia and sub-Saharan Africa examining service delivery, health
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going support. Types of non-adherence varied,
including missed doses, not taking medications on time, and not following treatment
instructions.

seeking behaviors, adherence, cost and other
factors affecting treatment for HIV-infected
adults and children. The design and implementation of these studies raised additional
questions regarding stigma, quality of life, and
sexual risk behaviors among persons living with
HIV on ART. This paper summarizes the key
findings and lessons learned from these projects
and provides recommendations for evidencebased programming and future research around
treatment for both children and adults.

A 2004 Horizons study of people living with
HIV in India found adherence to be significantly lower among patients with severe depression. Adherence was also lower among those
receiving free ART compared to patients in the
private sector who paid out-of-pocket for treatment. The study highlighted the need for better
patient education before initiating and during
ART [2, 3].

Lack of Provider Readiness,
Community Awareness,
Reduce Uptake and Adherence

Horizons’ research also revealed gaps in provider training, confidence, and competency, which
often prevented them from delivering ART services. In Thailand, a majority of ART providers
(i.e., doctors, nurses, and counselors) said they
had trouble counseling patients on drug side effects (Table 1). Nearly half of doctors reported
difficulties in diagnosing and managing side
effects and drug interactions, despite receiving
intensive training [4].

Horizons initially undertook exploratory studies to document the experiences of programs
that had already initiated ART services. These
studies identified patient retention and adherence to treatment as major challenges for
scale-up. For example, a 2002 situation analysis of the newly implemented Thai national
ART program in 15 hospitals in five northern
provinces documented a drop-out rate of 30
percent in the first six months of the program,
primarily because of side effects and lack of on-

In a pediatric study in three Kenyan provinces
selected because of high HIV prevalence and
the availability of pediatric HIV care services,

Table 1 Number and percentage of care providers who had difficulties in providing
Access To Care Project services in northern Thailand (2002)
Item

Doctors

Nurses

Pharmacists

Counselors

Total

n/N

n/N

n/N

n/N

n/N (%)

Diagnosis and management of
side effects

3/7

4/11

3/8

10/26 (38)

Management of drug interaction

3/7

1/7

2/7

6/21 (28)

Counseling on drug side effects

5/6

14/18

6/10

Interpreting laboratory results

1/7

5/13

2/4

Management of opportunistic
infections

2/8

1/6

3/4

Note: N = number of care providers who responded to the question, n = number of those who had difficulties.
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28/38 (74)
8/24 (33)
3/14 (20)

health workers revealed
ity of children had been
“We are grossly under
knowledge gaps and low
tested for HIV because
confidence regarding
they were chronically ill
supplying antiretroviral drugs
pediatric HIV diagnosis
or hospitalized with a
to children and our preprotocols, calculating
serious illness (Figure 1).
vention
of
mother-to-child
medication dosages,
Less than 2 percent of
transmission program is not
management of mulchildren receiving treatworking at this site. As a
tiple illnesses, prevenment were referred from
tion of mother-to-child
PMTCT programs [6].
result children are dying in
transmission of HIV
hoards.”
(PMTCT), and counselThe lack of follow-up
—Doctor (in a peri-urban setting)
ing [5]. A lack of stancare from PMTCT
interviewed for a study of pediatric
dardized or coordinated
HIV treatment in South Africa
programs was particutraining for health care
larly notable. A study
workers on the manageof HIV-positive pregment of pediatric HIV
nant and post-partum women in three high
was also identified in South Africa, where most
prevalence Indian states found that less than
doctors and nurses reported receiving no forone-third had been informed about CD4 testmal training in ART, instead using self-study
ing, and only 18 percent were informed about
from books and online courses [6].
the availability of ART during antenatal care.
Of the women with living children, 44 percent
reported that none of their children had been
A study exploring practices in pediatric ART
tested for HIV [7].
rollout at 16 sites in five South African provinces found that nearly all of the children
receiving ART were referred from community
The Kenya pediatric study also included a
clinics or from inpatient wards. The vast majorcommunity survey of primary caregivers of
children [5]. The study found
that while caregivers understood
the basics of HIV in adults,
Figure 1 Reasons for child HIV test in South Africa (n = 126)
knowledge about HIV infection
and symptoms in children was
low. Only half could name three
Case of TB
Hospitalization
symptoms indicative of pedi6%
40%
atric HIV infection. Although
PMTCT program
the majority were aware of treat5%
ment options for HIV-infected
Other
children and believed that these
5%
children could live into adulthood, less than two-thirds knew
where to access HIV testing and
treatment services for children
[5]. Health care costs (including
those related to transport, consultation fees, and medications)
and HIV-related stigma also
kept people from seeking care.
Child chronically ill
44%
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Directly observed therapy (DOT)
is a treatment strategy originally
developed for tuberculosis patients,
who must take all their medications
consistently and on time for up to
nine months to rid themselves of
the infection. In the standard DOT
approach, health workers or community volunteers watch clients as
they take their medication. One big
difference between treatments for
TB and HIV is that antiretroviral
medications for HIV must be taken
for life. A DOT strategy for AIDS
treatment is called DAART, for
“directly administered antiretroviral
therapy.” A DAART program includes observation of patients taking their medications, but less often
than for TB.

PAUL MUNYAO

Frequent Clinic
Visits, Enhanced
Counseling, Support
Adherence

Horizons researchers in Kenya found that DAART clients preferrred
clinic-based visits with health workers over home-based visits due to
confidentiality concerns and fear of stigma.

DAART to promote adherence to ART was asTo develop a DAART program, Horizons resessed among HIV-infected persons accessing
searchers explored the acceptability of home
services in coastal Kenya [9]. Horizons convisits by health care workers versus clinic visducted one of the first randomized, controlled
its among people with HIV, their preferred
studies of a clinic-based, DAART intervention
frequency of clinic visits per week, as well as
as a strategy to increase adherence to ART in a
the type of health worker they preferred for
resource-constrained setting in Kenya. The inhome visits. The majority of
tervention consisted of twice
people interviewed preferred
weekly clinic visits for the
clinic-based DAART, citing
first 24 weeks where patients
“It [DAART] reduced
confidentiality concerns and
met with DAART nurses
my anxiety about
risk of stigma within the
who watched them taking
drugs. I got used to
community associated with
their medicine, gave them
taking drugs. Also the
home health visits. Clients
more medications for the
also believed that clinic visits
drug dose timing; I was
time between visits, counted
afforded access to qualified
pills, and counseled them
able to follow the time
health care workers and felt
on ways to continue taking
strictly.”
a sense of personal control
their medication properly.
—33-year-old male patient
by visiting the clinic instead
Patients not getting DAART
who participated in the
of being visited at home [8].
Mombasa, Kenya study
received standard monthly
in-clinic follow up, includBuilding on this research,
ing counseling on taking
acceptability of a clinic-based approach to
medicine properly, and routine healthcare [10].
4
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cation at clinic and home visits; or (3) standard
care consisting of routine counseling and clinical follow up. The study found that enhanced
counseling with and without peer involvement
was effective in reducing drop-outs compared
with standard care at 12 months, and that at 12
months the peer intervention served to significantly increase patients’ belief in their ability to
take their ART properly [12].

In Thailand, Horizons researchers conducted a
randomized controlled study to evaluate interventions to help people take their antiretroviral
medications properly and reduce drop-outs
at 45 hospitals across four northern provinces
[12]. Hospitals were assigned to three groups:
(1) enhanced adherence counseling, including
patient education, side effect management, and
integration of medication into daily life; (2)
enhanced adherence counseling plus peer edu-

While clinic-based interventions designed to
increase an individual’s adherence to the ART
regimen are important, effective communitylevel interventions may also result in positive
outcomes for people living with HIV. The
AIDS Community and Education and Referral
Strategy (ACER), in the Zambian cities of
Lusaka and Ndola, represents one such effort.
The intervention aimed to raise community
awareness of HIV; strengthen communitybased support groups for people living with HIV by incorporating traditional healers,
church groups, and homebased care services; establish
referral mechanisms between
health facilities and the community; and used volunteer
peer treatment-support workers at clinics [13]. A Horizons
evaluation found few significant differences in knowledge
of HIV, disclosure of HIV
status, and adherence to ART
between communities that
experienced the program and
those that did not. It is likely
that an unrelated clinic-based
ART adherence program that
was introduced in the comparison sites by another organization diluted the effects of
the ACER intervention.

INTernational HIV/AIDS ALLIANCE

The study found that DAART was feasible and
effective in helping patients take their medicine properly during the intervention period
(Proportion with > 95% adherence: DAART:
92 percent vs. non-DAART: 80 percent; p =
0.012), but these effects were not sustained
after the intervention [8, 11]. DAART was
found to be particularly beneficial in patients
with moderate or severe depression in the first
24 weeks. The study findings raise further questions about the best way to optimize DAART
and whether it is most effective amongst a
sub-group of adults at risk for not taking their
medicines properly [11].

Horizons researchers explored the impact of the AIDS Community
and Education and Referral Strategy (ACER) in Zambia. Here, a
treatment support worker talks to community members.

Involving Community,
Helping Individuals
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Impact of ART on
People Living with
HIV

Stigma

Figure 2 Percent of participants with moderate to high stigma
scores at baseline and follow up after 12 months of
treatment in Mombasa, Kenya
73
*56

Percent

80
Horizons researchers nested
observational studies within
intervention studies to examine
60
change in HIV-related stigma
among people with HIV who
40
were receiving ART. These studies used an adapted HIV stigma
20
scale covering four domains:
personalized stigma, concerns
about revealing their HIV sta0
tus, negative self-image, and
concern with public attitudes
*p = 0.001
[14]. Common themes from
Horizons studies in Thailand
[12], Zambia [13], and Kenya
[15] showed that stigma decreased over time on
ART. For example in Kenya the proportion of
patients receiving ART reporting moderate to
high stigma declined from 73 percent prior to
initiating ART to 56 percent after 12 months
of treatment (Figure 2). Internalized stigma
appeared to be higher among female patients
compared to male patients prior to initiating
ART in Kenya [15] and Zambia [13].

Perceived quality of life
Perceived quality of life is a proxy for effectiveness of medication regimens; if HIV is effectively controlled, individuals have an increased
sense of well-being and engagement in routine
activities. Horizons’ researchers documented
significant increases in quality of life measures
over time among ART clients.
In Thailand, significant improvements in mental and physical health scores over 12 months
following counseling for antiretroviral medication adherence and peer support were observed
among patients in ART programs [12]. In
Kenya, significant improvements occurred
across general health perception; physical, so6
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Moderate to high (41–64)

cial, and cognitive functioning; pain; mental
health; and energy and fatigue.

Gender
Horizons studies noted gender differentials in
patient populations: more than 60 percent of
Kenyan and Zambian patients and more than
half of Thai patients were female [11–13]. Of
note, no gender differentials in adherence to
drug treatment were documented.

Sexual risk behavior
Researchers have expressed concern that effective treatment and the increases in well-being
and sexual activity that accompany it could
lead to an increase in unprotected sex among
people with HIV. Horizons research found
no evidence of increased sexual risk behavior
(i.e., multiple partners or unprotected sex) in
Kenya [16–18], Thailand [19], Zambia [13],
or India [3]. For example, in Kenya the proportion of sexually active participants who
reported unprotected sex with an unknown or
HIV-negative partner declined from 50 percent
at baseline to 28 percent after 12 months on

Baseline
(n = 183)
Follow up
(n = 181)

treatment (Figure 3). However, unprotected
sex is still prevalent, underscoring that the risk
of HIV transmission remains, particularly with
regular partners.

Testing and Validating
Research Methods
Horizons used a diverse range of research methodologies and study designs in its portfolio of
research on access to treatment (Appendix).
This includes measures and scales that were previously tested and validated, particularly those
pertaining to adherence to antiretroviral drug
regimens [20], depression [21], and quality of
life [22, 23]. In some studies, scales were adapted by a team of expert psychologists and social
scientists to more accurately reflect the local
cultural context, and translations and back
translations were pretested before application.
In the absence of a gold standard, measuring
adherence to antiretroviral drug regimens accurately is a challenge especially in resourcelimited settings. We recognize that patients
often overstate their adherence to drug regimens and under-report missed doses [24, 25].
Adherence studies often require that measures

such as pill counts and self reports are undertaken by clinic staff as a part of clinical management. Specialized training for interviewers
to ensure consistent and accurate data collection with regard to these measuring techniques
is essential. Newer methods such as computerized pill counts and audio computer-assisted
self-interviewing (ACASI) need to be explored
further.

Moving Forward
Horizons was among the first research programs to implement intervention studies on
antiretroviral medication adherence in developing countries. The evidence base provided
by Horizons’ early exploratory studies has
contributed to the design, strengthening, and
expansion of ART services. Horizons identified
training gaps and a lack of provider confidence
across several studies. Most treatment programs
provide one-time, intensive provider training at
their start. The importance of ongoing, needbased, and interactive training for providers
cannot be overemphasized. Training materials,
such as the adherence counseling manual developed by Horizons and used in Kenya [8], are
important in this endeavor, and have since been

Figure 3 Self-reported unprotected sex among sexually active participants in
Mombasa, Kenya
% reporting unprotected sex

100
80
60

Unprotected sex
77

Unprotected sex with
HIV-negative or
unknown status partners

63
50

40

28

20
0

Baseline (n = 107)

Follow up (n = 107)
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adapted by programs in Zambia, Tanzania,
South Africa, and Russia.
Human resource shortages in Africa are well
documented [26], and some treatment programs are run by clinical officers and nurses
instead of medical doctors. Expert consultation
is needed as treatment regimens become more
complicated. Future research will be needed
to evaluate models of training programs with
ongoing mentoring and access to specialist
services.
Horizons’ research has highlighted the lack of
integration among services for HIV testing,
TB testing, the prevention of mother-to-child
transmission of HIV, maternal health, and
ART. This information has been used by program managers and departments of health,
for example, in South African program planning efforts. In Kenya, the Kenya Network of
Women with AIDS (KENWA) is developing
interventions to increase community awareness of pediatric HIV and treatment. Efforts to
integrate HIV prevention care and treatment
services into existing maternal and child health
services require evaluation to identify best
practices and successful models for scale-up. As
programs race towards universal access to ART,
it is imperative to explore new approaches to
service delivery while simultaneously strengthening health systems and monitoring quality of
services.
DAART as a strategy to promote adherence has
been evaluated largely among people who have
HIV and are at risk of not taking their medications properly, such as injecting drug users [27–
29], patients in prison [30, 31] and to a limited
extent among the general population [32, 33].
Horizons has added to the scientific evidence
by rigorously evaluating clinic-based DAART
in a resource-limited setting. Given that improvements in adherence were not sustained
beyond the DAART intervention, further research is needed to determine the optimum duration of the intervention and ways to sustain
its effects. This includes evaluating DAART
8
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among clients who have not taken their antiretroviral medications properly over time, a
population for whom this resource-intensive
intervention might prove most beneficial.
HIV programs have long used HIV-positive
peers in developing countries as part of HIVprevention programs, for social support, and,
to a limited extent, for treatment-related activities. However, before the mid-2000s there was
no evaluation of a peer-based program designed
to support people in taking their HIV drugs
correctly. The Thailand Horizons study was one
of the first to show that such interventions are
more effective than standard care in increasing
people’s belief in their ability to take their drugs
correctly, lowering self-stigma, and improving
quality of life. This intervention has been introduced widely across the country with Global
Fund assistance. Such interventions are costlier
than traditional standard of care, and current
scale-up of ART programs may exclude such
ancillary services. Still, Horizons work in Kenya
and Thailand showed the value of ancillary services, including, DAART and peer education
and support.
Horizons studies were undertaken as ART
programs first rolled out, and most patients
presented with advanced HIV disease, a factor
that undoubtedly stimulated adherence. As the
epidemic matures, programs are increasingly
managing patients on long-term treatment
with emerging evidence of poor adherence to
drug regimens [34]. Patients in resource-poor
settings will experience side effects and other
conditions associated with long-term ART, as
has been documented in western countries [3,
35–37]. These include diabetes and lipodystrophy, a redistribution of fat tissue on the body.
It is not uncommon for people on long-term
antiretroviral treatment, for example, to have
gaunt faces and/or a “hump” on the back of
their neck. Second-generation drug adherence
studies in developing countries will need to
examine these factors, as well as viral resistance,
and their intersection with quality of life and
stigma. For example, lipodystrophy might

Melissa may/population council

interventions to increase the use of
pediatric HIV testing and treatment
services in Kenya, and has worked in
South Africa on a family-centered approach to expand HIV testing of children and the provision of pediatric
care and treatment. Drug adherence
programs for pediatric populations
need to be developed and evaluated in
Africa as more HIV-infected children
receive treatment. Age is also an important consideration, as young children, adolescents, and emancipated
minors will have differing abilities to
take their medications correctly.

A Horizons study in Chang Mai emphasized the need for improved data
collection methods and tools to measure adherence to drug regimens.

serve as an identifier for HIV-positive individuals in the community, resulting in stigma and
discrimination.
Although Horizon’s studies provided no evidence of an increase in sexual risk behavior
among people with HIV who are on treatment,
unprotected sex in regular partner relationships
is prevalent, and the risk of HIV transmission
is still a concern. Treatment programs need to
emphasize risk reduction, condom use, and
partner testing. Population Council researchers
developed a “prevention with positives” intervention to integrate prevention and treatment
services in Kenya to address these issues.
Despite intense recent attention to pediatric
treatment, access to treatment for HIV infected
children has lagged behind that for adults [38,
39]. Priority areas for research have included
evaluation of interventions to increase diagnosis of HIV among children and to facilitate
early treatment for HIV-infected children. The
Population Council is supporting community

Horizons’ intervention studies also
underscored the challenges of conducting operations research in field
settings. Of particular importance is
the need for improved data collection methods and tools to accurately
measure drug regimen adherence.
Horizons’ partners at Chiang Mai University
developed a computer-based program to increase the accuracy of pill counts; such methods need to be evaluated. ACASI has been
used in other Population Council studies addressing sensitive topics and could be applied
to treatment research in order to improve the
accuracy of self-reports of adherence. Selecting
HIV-infected patients to participate in studies is challenging as people with HIV cannot
be identified or reached in communities for
reasons of confidentiality. Horizons’ researchers
had to use convenience or quota sampling to
overcome this problem [40]. Lastly, as in other
sectors, sustaining interventions after initial
funding ends is a challenge for both programs
and researchers. For example, peer volunteers
or community health workers play a key role
in enhancing service delivery, but may require
some form of compensation to continue delivering interventions.
Global efforts to expand access to HIV treatment in low- and middle-income countries
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have resulted in significant progress. An estimated 42 percent of the 9.5 million people in
need of ART had access in 2008 [41]. While
positive, this figure reflects the monumental
task ahead to achieve universal access by 2015.
Horizons’ research has made major contributions to the body of scientific evidence about
ART provision and adherence, has answered
key research questions, and has provided
directions for next steps to reach universal
access.

10
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Appendix
Sample characteristics and study design among Horizons studies, 2002–2008
Study title and country

Year of
study

Target
population

Sample size

Type of
study

Sampling
methodology

A rapid situation analysis of
the provision of highly active
antiretroviral therapy to persons
living with HIV/AIDS by the
Ministry of Public Health’s Access
to Care Project in Northern
Thailand2

2002

HIV infected
adults

15 ART clinics
120 PLHA

RSA
Descriptive

Purposive sampling

Formative assessment of the
acceptability of modified DOT
strategy to promote adherence to
ART among PLHA in Mombasa,
Kenya9

2002

HIV infected
adults

38 PLHA

Qualitative

Purposive sampling

Reproductive health services in
KwaZulu Natal, South Africa: A
situation analysis study focusing on
HIV/AIDS services42

2002–
2003

HIV infected
adults

98 health facilities
418 clients
299 health providers

RSA

Operations research around the
introduction of antiretrovirals in
the management of HIV infected
individuals in Mombasa, Kenya8, 10,

2003–
2006

HIV infected
adults

234 PLHA

Prospective

Assessment of adherence to
treatment and sexual risk behaviour
among HIV-positive patients
receiving antiretroviral therapy—A
diagnostic study in India3, 4

2004

HIV infected
adults

310 PLHA on
treatment

Descriptive

Quota sampling

Community education and
referral: Supporting adherence
to antiretroviral treatment and
prevention for people with HIV in
Zambia13

2004–
2007

HIV infected
adults

1,200 community
members
500 PLHA on
treatment

Prospective

Cluster sampling of
community members from
households

Descriptive

Simple random sampling
of health facilities

Descriptive

Convenience sampling of
respondents

Randomised
controlled study
(2 arms)

11, 15–18

Quota sampling with
randomized assignment

Pre- and postintervention control
evaluation
Quota sampling of
PLHA

Access to Antiretroviral Therapy
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12

Reducing drop-outs and increasing
adherence-rates among persons
living with AIDS (PLA) on
antiretroviral therapy (ART) in
northern Thailand12

2004–
2007

Exploring current practices in
pediatric ARV rollout and
integration with early childhood
programs in South Africa: A rapid
situation analysis6

2005

Diagnostic operations research to
inform the national initiative on
improving access to treatment,
care and support for HIV-positive
women and their families in India7

2005–
2006

HIV infected
315 HIV infected
pregnant or
females
post partum
(<24 months)
women

Descriptive

Convenience

Exploring models of delivering ART
and integration of ART with TB
services in South Africa43

2006

HIV infected
adults

14 health facilities
262 PLHA
43 health providers

RSA

Convenience sampling

Healthy Start Pediatric HIV Study:
A diagnostic study investigating
barriers to HIV treatment and care
among children in Kenya5

2007

HIV infected
children

1,180 caregivers of
children <15 yrs
103 health workers

Descriptive

Access to Antiretroviral Therapy

HIV infected
adults

45 hospitals
753 PLHA

Randomized
controlled study
(3 arms)

Convenience sampling
of facilities with random
assignment to groups
Quota sampling of
PLHA

HIV infected
children

16 ARV programs
126 caregivers
74 HCW

RSA

Convenience sampling

Descriptive

Descriptive
Cluster sampling of
households
Convenience sampling of
health workers
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